CMV Infection and its Prevention with Specific Immunoglobulins
Patients undergoing bone marrow transplantation for hematologic disorders are severely immunocompromised by the intensive chemotherapy and total body irradiation used in preparation for the transplant. Interstitial pneumonia occurs as a complication in approximately 40% of all bone marrow transplant recipients and is fatal in 70% of cases (1–3). Cytomegalovirus (CMV) is the most common pathogen associated with the interstitial pneumonia and can be identified in 50–70% of cases.
Unable to display preview. Download preview PDF.
- 1.Winston DJ, Bryson YJ, Ho WG, Territo MD, Golde DW, Gale RP. Interstitial pneumonia and cytomegalovirus infection after bone marrow transplantation. In: Gale RP, Fox GE, eds. Biology of bone marrow transplantation, New York, Academic Press, 1980: 83–95.Google Scholar
- 2.Winston DJ, Ho WG, Champlin RE, Gale RP. Treatment and prevention of interstitial pneumonia associated with bone marrow transplantation. In: Gale RP, Fox GE, eds. Recent advances in bone marrow transplantation. UCLA Symposia on Molecular and Cellular Biology, Vol. 7, New York: Alan R. Liss Inc. (in press).Google Scholar
- 10.Winston DJ, Ho WG, Ramussen LE, et al. Use of intravenous immune globulin in patients receiving bone marrow transplants. J Clin Immunol (Suppl) 1982; 2: 425–75.Google Scholar
- 11.Gale RP. Current status of bone marrow transplantation in acute leukemia. Transplant Proc 1979; 9: 1920–3.Google Scholar
- 14.Casey HL. Adaptation of laboratory branch complement-fixation method to micro technique. Public monograph no 74 Washington DC: Government Printing Office, 1965.Google Scholar
- 17.O’Reilly RJ, Reich L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation - Preliminary results. Transplant Proc 1983; 15: 1405–11.Google Scholar